Sun Pharma Gets CDSCO Panel Nod To study Semaglutide solution for Injection
Written By : Dr. Divya Colin
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-04-19 12:30 GMT | Update On 2025-04-19 12:30 GMT
Advertisement
New Delhi: Considering the bioequivalence (BE) study report of the antidiabetic drug Semaglutide solution for injection (synthetic origin) 0.25mg /0.5ml, 0.5 mg /0.5ml, 1 mg/0.5 ml, 1.7 mg/0.75 ml and 2.4 mg/0.75 ml, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to the drug major Sun Pharma for conducting a Phase III clinical trial study.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.